华润医药(03320.HK) 公布，附属东阿阿胶发盈喜，预计2024年度净利润介乎15亿至16亿人民币，相较上年度录得11.51亿人民币。利润增长主要由于公司持续深入实践“价值重塑、业务重塑、组织重塑、精神重塑”，实现经营业绩稳步增长。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-17 16:25。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/29 | 中期业绩 | 股息：人民币 0.0830 (约相等于 0.0908 港元, 可选择港币或该等货币组合) |
| 2024/03/26 | 末期业绩 | 股息：人民币 0.1540 (约相等于 0.1697 港元, 可选择HKD或该等货币组合) |
| 2023/08/31 | 中期业绩 | 无派息 |
| 2023/03/30 | 末期业绩 | 股息：港元 0.1600 (约相等于 人民币 0.14元, 可选择以人民币收取) |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.